FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2270125291> ?p ?o ?g. }

• W2270125291 endingPage "414" @default.
• W2270125291 startingPage "404" @default.
• W2270125291 abstract "Paediatric optic pathway gliomas are low-grade brain tumours characterized by slow progression and invalidating visual loss. Presently there is no strategy to prevent visual loss in this kind of tumour. This study evaluated the effects of nerve growth factor administration in protecting visual function in patients with optic pathway glioma-related visual impairment. A prospective randomized double-blind phase II clinical trial was conducted in 18 optic pathway glioma patients, aged from 2 to 23 years, with stable disease and severe visual loss. Ten patients were randomly assigned to receive a single 10-day course of 0.5 mg murine nerve growth factor as eye drops, while eight patients received placebo. All patients were evaluated before and after treatment, testing visual acuity, visual field, visual-evoked potentials, optic coherence tomography, electroretinographic photopic negative response, and magnetic resonance imaging. Post-treatment evaluations were repeated at 15, 30, 90, and 180 days Brain magnetic resonance imaging was performed at baseline and at 180 days. Treatment with nerve growth factor led to statistically significant improvements in objective electrophysiological parameters (electroretinographic photopic negative response amplitude at 180 days and visual-evoked potentials at 30 days), which were not observed in placebo-treated patients. Furthermore, in patients in whom visual fields could still be measured, visual field worsening was only observed in placebo-treated cases, while three of four nerve growth factor-treated subjects showed significant visual field enlargement. This corresponded to improved visually guided behaviour, as reported by the patients and/or the caregivers. There was no evidence of side effects related to nerve growth factor treatment. Nerve growth factor eye drop administration appears a safe, easy and effective strategy for the treatment of visual loss associated with optic pathway gliomas." @default.
• W2270125291 created "2016-06-24" @default.
• W2270125291 creator A5000243882 @default.
• W2270125291 creator A5014523878 @default.
• W2270125291 creator A5018168557 @default.
• W2270125291 creator A5025572626 @default.
• W2270125291 creator A5046456133 @default.
• W2270125291 creator A5050985208 @default.
• W2270125291 creator A5055382130 @default.
• W2270125291 creator A5056134895 @default.
• W2270125291 creator A5059514574 @default.
• W2270125291 creator A5060154255 @default.
• W2270125291 creator A5060670648 @default.
• W2270125291 creator A5067097471 @default.
• W2270125291 creator A5071142963 @default.
• W2270125291 creator A5072399329 @default.
• W2270125291 creator A5084397197 @default.
• W2270125291 creator A5087361148 @default.
• W2270125291 creator A5088126168 @default.
• W2270125291 date "2016-01-14" @default.
• W2270125291 modified "2023-10-03" @default.
• W2270125291 title "Nerve growth factor improves visual loss in childhood optic gliomas: a randomized, double-blind, phase II clinical trial" @default.
• W2270125291 cites W129913397 @default.
• W2270125291 cites W1519755024 @default.
• W2270125291 cites W1588547191 @default.
• W2270125291 cites W1608424455 @default.
• W2270125291 cites W1714355435 @default.
• W2270125291 cites W1954424103 @default.
• W2270125291 cites W1964696564 @default.
• W2270125291 cites W1984302365 @default.
• W2270125291 cites W1986535403 @default.
• W2270125291 cites W1989661280 @default.
• W2270125291 cites W2008350281 @default.
• W2270125291 cites W2010710399 @default.
• W2270125291 cites W2017812089 @default.
• W2270125291 cites W2020375422 @default.
• W2270125291 cites W2028831925 @default.
• W2270125291 cites W2029892893 @default.
• W2270125291 cites W2031681284 @default.
• W2270125291 cites W2038151131 @default.
• W2270125291 cites W2043244708 @default.
• W2270125291 cites W2044970238 @default.
• W2270125291 cites W2055605243 @default.
• W2270125291 cites W2064313309 @default.
• W2270125291 cites W2066602307 @default.
• W2270125291 cites W2067208759 @default.
• W2270125291 cites W2068383018 @default.
• W2270125291 cites W2068955716 @default.
• W2270125291 cites W2075029484 @default.
• W2270125291 cites W2088285843 @default.
• W2270125291 cites W2118220465 @default.
• W2270125291 cites W2122945372 @default.
• W2270125291 cites W2132374129 @default.
• W2270125291 cites W2136409632 @default.
• W2270125291 cites W2142163465 @default.
• W2270125291 cites W2143216989 @default.
• W2270125291 cites W2145290169 @default.
• W2270125291 cites W2148334422 @default.
• W2270125291 cites W2159293041 @default.
• W2270125291 cites W2159799352 @default.
• W2270125291 cites W2160483372 @default.
• W2270125291 cites W2278845798 @default.
• W2270125291 doi "https://doi.org/10.1093/brain/awv366" @default.
• W2270125291 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26767384" @default.
• W2270125291 hasPublicationYear "2016" @default.
• W2270125291 type Work @default.
• W2270125291 sameAs 2270125291 @default.
• W2270125291 citedByCount "37" @default.
• W2270125291 countsByYear W22701252912016 @default.
• W2270125291 countsByYear W22701252912017 @default.
• W2270125291 countsByYear W22701252912018 @default.
• W2270125291 countsByYear W22701252912019 @default.
• W2270125291 countsByYear W22701252912020 @default.
• W2270125291 countsByYear W22701252912021 @default.
• W2270125291 countsByYear W22701252912022 @default.
• W2270125291 countsByYear W22701252912023 @default.
• W2270125291 crossrefType "journal-article" @default.
• W2270125291 hasAuthorship W2270125291A5000243882 @default.
• W2270125291 hasAuthorship W2270125291A5014523878 @default.
• W2270125291 hasAuthorship W2270125291A5018168557 @default.
• W2270125291 hasAuthorship W2270125291A5025572626 @default.
• W2270125291 hasAuthorship W2270125291A5046456133 @default.
• W2270125291 hasAuthorship W2270125291A5050985208 @default.
• W2270125291 hasAuthorship W2270125291A5055382130 @default.
• W2270125291 hasAuthorship W2270125291A5056134895 @default.
• W2270125291 hasAuthorship W2270125291A5059514574 @default.
• W2270125291 hasAuthorship W2270125291A5060154255 @default.
• W2270125291 hasAuthorship W2270125291A5060670648 @default.
• W2270125291 hasAuthorship W2270125291A5067097471 @default.
• W2270125291 hasAuthorship W2270125291A5071142963 @default.
• W2270125291 hasAuthorship W2270125291A5072399329 @default.
• W2270125291 hasAuthorship W2270125291A5084397197 @default.
• W2270125291 hasAuthorship W2270125291A5087361148 @default.
• W2270125291 hasAuthorship W2270125291A5088126168 @default.
• W2270125291 hasBestOaLocation W22701252911 @default.
• W2270125291 hasConcept C118487528 @default.
• W2270125291 hasConcept C126838900 @default.
• W2270125291 hasConcept C142724271 @default.

• next